Carnegie Mellon’s Joel McManus and Pitt’s Robert Nicholls received a $162,000 grant from the Foundation for Prader-Willi Research to study the regulation and function of a key gene that is usually ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

Ivy Country Corner's Shell gas pumps, a slice of the profits will go to helping kids like 3-year-old Catalina Valenti, who ...

DelveInsight’s "Prader–Willi Syndrome Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of PWS, historical and forecasted epidemiology as ...

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests. The FDA has extended the review period for the NDA for DCCR tablets for the treatment ...

for the treatment of adults and children aged 4 years and older with Prader-Willi syndrome (PWS) who have hyperphagia. The investigational product is an extended-release formulation of diazoxide ...

The treatment is designed for individuals aged four and older with Prader-Willi syndrome who experience hyperphagia. This extension was prompted by the FDA's determination that responses to recent ...

(SLNO) Tuesday announced that the FDA has extended the review period for the New Drug Application for DCCR tablets targeted at patients with Prader-Willi syndrome. DCCR is a proprietary extended ...

There is ACP-101 for the treatment of patients with Prader-Willi Syndrome [PWS] and then ACP-204 for Alzheimer's Disease [AD] psychosis. With a continued increase of sales of its two regulatory ...